drugset / Trial / NCT00004689
Phase II Study of Amithiozone (Thiacetazone) for Patients With Mycobacterium Avium Complex Pulmonary Disease
RandomizedOpen-labelTreatment
Summary
OBJECTIVES: I. Determine the bacteriological activity of amithiozone against Mycobacterium avium complex (MAC) pulmonary disease. II. Define the ability of amithiozone to improve clinical outcomes in patients with MAC infection. III. Determine the safety and tolerance of amithiozone with chronic dosing in these patients. IV. Assess the contribution of clarithromycin, streptomycin, rifampin, ethambutol, kanamycin, and amithiozone in the treatment of pulmonary MAC infection.
Timeline
- Start
- 1991-01
- Primary completion
- —
- Completion
- 1998-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Clarithromycin | Small molecule | — | — |
| Subject | Ethambutol | Small molecule | — | — |
| Subject | Rifampicin | Small molecule | — | — |
| Subject | amithiozone | Small molecule | — | — |
| Subject | streptomycin | Other / unclassified | — | — |